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Abstract
Background: Optimal management and outcome of primary gastric lymphoma (PGL) have not been well defined
in the rituximab era. This study aimed to analyze the clinical characteristics, prognostic factors, and roles of
different treatment modalities in Chinese patients with PGL.
Methods: The clinicopathological features of 83 Chinese patients with PGL were retrospectively reviewed. Staging
was performed according to the Lugano staging system for gastrointestinal non-Hodgkin’s lymphoma.
Results: The predominant pathologic subtype among Chinese patients with PGL in our study was diffuse large B
cell lymphoma (DLBCL), followed by mucosa-associated lymphoid tissue (MALT) lymphoma. Among the 57 patients
with gastric DLBCL, 20 patients (35.1%) were classified as the germinal center B cell-like (GCB) subtype and 37
patients (64.9%) as the non-GCB subtype. The 83 patients had a five-year overall survival (OS) and event-free
survival (EFS) of 52% and 59%, respectively. Cox regression analysis showed that stage-modified international
prognostic index (IPI) and performance status (PS) were independent predictors of survival. In the 67 B-cell
lymphoma patients who received chemotherapy, 36 patients treated with rituximab (at least 3 cycles) had a mean
OS of 72 months (95% CI 62-81) versus 62 months (95% CI 47-76) for patients without rituximab treatment (P =
0.021).
Conclusion: The proportion of Chinese gastric DLBCL cases with non-GCB subtype was higher than the GCB
subtype. Stage-modified IPI and PS were effective prognostic factors in Chinese patients with PGL. Our data
suggested that primary gastric B-cell lymphoma might have an improved outcome with rituximab in addition to
chemotherapy. More studies are necessary, preferentially large prospective randomized clinical trials to obtain more
information on the impact of the rituximab in the primary gastric B-cell lymphoma.
Background
Primary gastric lymphoma (PGL) originates in the
stomach, with or without perigastric and/or abdominal
lymph node involvement [1]. PGL is an uncommon
tumor, accounting for less than 15% of gastric malignan-
cies and about 2% of all lymphomas [2]. However, PGL
is the most common extranodal lymphoma, representing
30%-40% of all extranodal lymphomas and 60%-75% of
all gastrointestinal lymphomas [3-6]. The incidence of
PGL is progressively increasing.
The main histological subtypes of PGL (more than
90% of cases) are diffuse large B-cell lymphoma
(DLBCL) and marginal zone B-cell lymphoma of the
mucosa-associated lymphoid tissue (MALT) [7,8]. Heli-
cobacter pylori infection has been implicated in the
pathogenesis and treatment of gastric MALT lymphoma,
but its role in gastric DLBCL is uncertain[9,10]. Various
therapeutic aspects for primary gastric lymphomas,
including antibiotic therapy, rituximab therapy, combin-
ing chemotherapy with radiotherapy or occasionally
resection, are still controversial and several questions
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front-line treatment in patients with PGL. However,
recent clinical trial results supported that organ preser-
vation with chemotherapy combined with radiation
could yield equal results to surgery combined with
radiation in PGL patients [11]. Among others, clinical
information of PGL warrants better clarification. Thus,
we decided to contribute to this field by investigating
the clinical characteristics, prognostic factors, and the
roles of different treatment modalities of PGL in the
rituximab era.
Methods
Patients and Staging
We carried out a retrospective study of 83 PGL patients
diagnosed at the Sun Yat-sen University Cancer Center,
China from January 2001 to June 2008. The study was
approved by the Institutional Review Board (IRB) of Sun
Yat-Sen University Cancer Center. All the cases satisfied
the PGL diagnosis criteria defined by Lewin et al. [12],
and were identified based on the World Health Organi-
zation (WHO) classification of Tumor of Hematopoietic
and Lymphoid Tissues [7]. All of the patients were
negative in the serologic detection of Human immuno-
deficiency virus (HIV).
All patients were staged according to the Lugano sta-
ging system for gastrointestinal non-Hodgkin’sl y m -
phoma [8]. The diagnostic workup included the
patients’ history, performance status according to the
Eastern Cooperative Oncology Group (ECOG) scale,
physical examination, baseline endoscopy or barium
meal examination, gastric mucosal biopsies or gastrect-
omy, complete blood cell count, biochemical profile,
measurement of serum lactate dehydrogenase (LDH),
computed tomography scans of the thorax, abdomen
and pelvic cavity, as well as bone marrow aspiration and
biopsy. We defined bulky disease as any mass of 10 cm
or more in maximal diameter. Low hemoglobin was
defined as < 120 g/L, low albumin as < 35 g/L, and high
LDH as > 245 U/L.
Imunohistochemical Study and Research of H. Pylori
Formalin-fixed paraffin-embedded tissues obtained from
patients diagnosed with DLBCL were analyzed for
immunoreactivity towards CD20 (clone L26, DAKO,
Glostrup, Denmark), BCL6 (clone P1F6, Novocastra,
Newcastle, UK), CD10 (clone 56C6, Novocastra, New-
castle, UK) and MUM1/IRF4 (polyclonal, Santa Cruz
B i o t e c h n o l o g y ,S a n t aC r u z ,C A ,U S A ) .W ea n a l y z e dt h e
tissues for immunoreactivity towards CD10, bcl-6, or
MUM1 according to the immunophenotypic profile cri-
teria of DLBCL described by Hans et al. [13]. Cases
where 30% or more of the tumor cells were immunor-
eactive with a given antibody were considered positive
for that antigen [13]. The immunohistochemical review
was performed independently by 2 histopathologists.
Patients were considered H. pylori positive if either the
serology or histology was positive for H. pylori.
Stage-modified International Prognositic Index (IPI)
Stage-modified IPI was designed according to the IPI
(international prognostic index) in which the original
Ann Arbor stage II was substituted by Lugano staging
system for gastrointestinal non-Hodgkin’sl y m p h o m a
[14].
Response Criteria
We used imaging studies and endoscopic examination in
order to perform response evaluation. Response criteria
were defined according to the International Working
Group Recommendations [15]. Complete remission
(CR) was defined as the complete disappearance of all
physical and radiological evidence of disease for at least
four weeks. An endoscopic evaluation and biopsies of
stomach should be carried out to confirm a CR. Addi-
tionally, patients not in CR at the end of treatment were
considered treatment failures. Overall survival (OS) was
measured from the date of diagnosis until the date of
death due to any cause or the date of final follow-up in
the survivors. Event-free survival (EFS) was calculated
from the date of diagnosis to the date of treatment fail-
ure, relapse, evidence of disease progression or death
due to any cause.
Statistical Analysis
Primary endpoints of our analysis were OS and EFS.
Survival curves and the univariate analysis were analyzed
b yt h eK a p l a n - M e i e rm e t h o d .T h ep r o g n o s t i cv a l u eo f
different variables for clinical outcome was estimated by
multivariate analysis using the Cox regression model.
Clinical parameters with corresponding P-value of less
than 0.05 in univariate analysis were included in multi-
variate analysis. A 2-tailed P value < 0.05 assessed by
the log-rank test was considered statistically significant.
SPSS 16.0 for Window Software was used for all statisti-
cal analyses.
Results
Clinical and Histological Features
Patients’ characteristics are detailed in Table 1. Of the
83 patients recruited into the study, 45 were male and
38 were female with a median age of 52 years (range
15-81 years). The most common complaint at presenta-
tion was epigastric pain. Thirty cases (36%) of the
patients presented with melena and fifteen cases (18%)
with nausea/vomiting. Hematemesis and ileus were
uncommon at presentation. None of the patients experi-
enced perforation prior to treatment. In our study, we
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Page 2 of 10found that the antrum was the most commonly involved
site (53 cases, 64%), followed by the corpus (44 cases,
53%). Two cases were diagnosed with stump involve-
ment. Both had a history of gastric ulcer and underwent
subtotal gastrectomy 20 and 22 years prior to study
participation, respectively.
According to the results of the immunophenotypic pro-
file in DLBCL, we grouped the fifty-seven patients (69%)
with DLBCL into the germinal center B-cell-like group
(GCB) and the non-GCB group. We demonstrated that of
the 57 patients with DLBCL, 20 patients (35%) were classi-
fied as the GCB subtype and 37 cases (65%) as the non-
GCB subtype. The ratio of GCB to non-GCB phenotypes
was about 1:1.85. MALT lymphoma accounted for 17% of
all the patients studied (14 cases). Other B cell histological
subtypes were found in 4 cases, including 3 cases of Bur-
kitt’s lymphoma and 1 case of mantle lymphoma. Eight
cases (9.6%) were diagnosed as T-cell NHL, with 1 case of
precursor T lymphoblastic lymphoma, 3 cases of anaplas-
tic large cell lymphoma (ALCL), and 4 cases of unspecified
peripheral T-cell lymphoma (U-PTL).
Among the 61 patients who were tested for H. pylori,
there were 43 cases with DLBCL, 12 cases with MALT,
and 6 cases with other pathologic subtypes. Forty-nine
study patients (80%) tested positive for H. pylori. The
DLBCL and MALT lymphoma groups comprised 79%
(34/43) and 92% (11/12) of the H. pylori positive
patients respectively.
Using the Lugano staging system, 24 patients (29%)
p r e s e n t e da tS t a g eI .O ft h e1 9p a t i e n t s( 2 3 % )w h op r e -
sented with local or distant nodal involvement, 5 were
diagnosed with local lymph node involvement (stage
II1), and 14 had distant abdominal nodal extension
(stage II2). There were also 20 cases (24%) who were at
stage IIE and 20 cases (24%) at stage IV with advanced
disease. Table 2 represents the classification of patients
into the adverse factors groups and three high-risk
groups of stage-modified IPI.
Treatment Modalities
Table 3 shows the treatment modalities of all patients.
Of the 28 patients who underwent surgery, 18 patients
had radical surgery and 10 patients had palliative
Table 1 Baseline Characteristics of 83 Chinese Patients
with PGL
Characteristics Number of assessable
patients (%)
Age (years)
Median 52
Range 15-81
Sex
Male 45 (54.2)
Female 38 (45.8)
Ratio, male to female 1.2
Presenting Symptom
1
Abdominal pain 69 (83.1)
Melena 30 (36.1)
Nausea or vomitting 15 (18.1)
Hematemesis 6 (7.2)
Ileus 1 (1.2)
Perforation 0
B symptoms 56 (67.5)
Bulky Disease 21 (25.3)
Involvement within the stomach
2
Cardia 13 (15.7)
Fundus 15 (18.1)
Corpus 44 (53.0)
Antrum 53 (63.9)
Pylorus 12 (14.5)
Stump 2 (2.4)
Histopathology
B cell subtypes 75 (90.4)
Diffuse large B cell lymphoma 57 (68.7)
GCB subtype 20 (20/57, 35.1)
Non-GCB subtype 37 (37/57, 64.9)
Ratio, GCB to Non-GCB 1:1.85
MALT lymphoma 14 (16.9)
Burkitt lymphoma 3 (3.6)
Mantle cell lymphoma 1 (1.2)
T cell subtypes 8 (9.6)
Peripheral T-cell lymphoma,
unspecified
4 (4.8)
Anaplastic large cell lymphoma 3 (3.6)
Precursor T lymphoblastic
lymphoma
1 (1.2)
H. pylori infection
3 49 (49/61, 80.3)
Laboratories at first visit
Leucocytopenia (< 4.0 × 10
9/L) 7 (8.4)
Neutropenia (< 2.0 × 10
9/L) 8 (9.6)
Lymphocytopenia (< 1.0 × 10
9/L) 15 (18.1)
Low hemoglobin (< 120 g/L) 43 (51.8)
Low albumin (< 35 g/L) 24 (28.9)
Increased LDH (> 245 U/L) 40 (48.2)
Lugano Staging
I 24 (28.9)
II1 5 (6.0)
II2 14 (16.9)
Table 1: Baseline Characteristics of 83 Chinese Patients
with PGL (Continued)
IIE 20 (24.1)
IV 20 (24.1)
Number total > 83, more than 1 symptom can be observed in the same
patient.
Number total > 83, more than 1 involved site can be found in the same
stomach.
61 of 83 cases received H. pylori detection.
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Page 3 of 10surgery. Four of these 28 cases underwent emergency
surgery due to chemotherapy related complications,
including perforation, acute upper gastrointestinal
hemorrhage and intestinal obstruction. Of the two
patients with surgical complications: one had reflux eso-
phagitis and the other had stenosis of the stoma.
Of the 74 patients who received chemotherapy, 29
patients received only chemotherapy and 45 patients
received chemotherapy combined with other treatment
modalities. CHOP (cyclophosphamide, doxorubicin, vin-
cristine and prednisone) or CHOP-like regimens were
t h em o s tf r e q u e n t l yu s e df i r s t - l i n et r e a t m e n ti n6 7
patients (49 patients with DLBCL, 12 patients with
MALT lymphoma, 2 cases with Burkitt lymphoma, 1
case with mantle cell lymphoma, 1 case with precursor
T lymphoblastic lymphoma, 1case with anaplastic large
cell lymphoma and 1 case with peripheral T-cell lym-
phoma, unspecified). Other regimens included EPOCH
(etoposide, prednisone, vincristine, doxorubicin and
cyclophosphamide) (3 cases with DLBCL, 1 case with
anaplastic large cell lymphoma and 1 case with periph-
eral T-cell lymphoma, unspecified), IMVP-16 (ifosfa-
mide, methotrexate and etoposide) (1 case with
peripheral T-cell lymphoma, unspecified) and GEMOX
(gemcitabine and oxaliplatin) (1 case with peripheral T-
cell lymphoma, unspecified). Thirty-six patients treated
with rituximab for at least 3 cycles (ranged from 3 to 8
cycles), with a median of 5 cycles. Chemotherapy related
complications such as acute upper gastrointestinal
hemorrhage and intestinal obstruction, perforation and
worsening of performance status (excluding hematologi-
cal toxicity) were observed in 9 of 74 patients who
received chemotherapy. There were 3 cases with acute
bleeding, 1 case with ileus, 2 cases with acute bleeding
and ileus, 2 cases with perforation, and 1 case with wor-
sening of performance status. Four of these cases under-
went emergency surgery due to acute bleeding, ileus or
perforation. Two patients died due to acute upper gas-
trointestinal hemorrhage related to the treatment. Of
the twenty patients (24%) who received radiotherapy,
eighteen received it as adjuvant treatment followed by
chemotherapy, while two patients had radiotherapy as
palliative treatment after disease progression.
Two patients who were diagnosed as MALT lym-
phoma (stage I) and H. pylori positive were only treated
Table 3 Treatment Modalities of 83 Chinese Patients with PGL
Treatment modalities Number of
patients
Histological Subtypes
(no. of patients)
Lugano Staging
(no. of patients)
B-cell lymphoma
(n = 75)
T-cell
lymphoma
(n = 8)
I-II1
(n = 29)
II2-IV
(n = 54)
Single therapy 32 30 2 16 16
Surgery 1 1 0 0 1
Chemotherapy 29 27 2 14 15
H. pylori eradication 2 2 0 2 0
Combined therapy 45 40 5 13 32
Surgery + chemotherapy 23 20 3 6 17
Surgery + chemotherapy + H. pylori eradication 2 1 1 1 1
Chemotherapy + radiotherapy 14 13 1 3 11
Chemotherapy + radiotherapy + H. pylori eradication 4 4 0 3 1
Surgery + chemotherapy + radiotherapy 2 2 0 0 2
Supportive care only 651 2 4
Treatment in both single and combined therapy
Surgery 28 24 4 7 21
Chemotherapy 74 67 7 27 47
Radiotherapy 20 19 1 6 14
H. pylori eradication 8 7 1 6 2
Table 2 Patients’ Characteristics According to
Stage-modified IPI
Characteristics (adverse factors of all
patients)
Number of patients
(%)
Age > 60 years 24 (28.9)
Serum LDH > 245 U/L 40 (48.2)
ECOG Performance Status ≥ 2 9 (10.8)
Lugano stage ≥ II2 54 (65.1)
Extranodal site involvement (excluding
stomach) ≥ 1
9 (10.8)
Risk groups (number of risk factors)
Low risk group (0-1) 38 (45.8)
Intermediate risk group (2) 26 (31.3)
High risk group (3-5) 19 (22.9)
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sion as evaluated by imaging studies and endoscopic
examinations at their 41 and 43 month follow-up visits,
respectively. Six of the of 83 patients (7.2%) patients
received supportive care due to their poor performance
status, and all of them died of tumor progression.
Survival and prognostic factors
Twenty-seven of the 83 patients (32%) died in a median
f o l l o w - u pp e r i o do f4 8m o n t h s( r a n g e2 - 9 5m o n t h s ) .
Seventeen of these patients died of tumor progression, 2
died of chemotherapy related hemorrhage, 3 died of
non-malignancies and 5 died of unknown causes.
An actuarial analysis showed that 1-year and 5-year
estimates of overall survival were 89% and 59%, respec-
tively, with a mean survival time (MST) of 65 months
(95% confidence interval, CI 56-74) (Figure 1). In
patients with poor performance status (PS ≥ 2), the
mean survival time was 17 months (95% CI 5-29) versus
71 months (95% CI 62-80) for those with better perfor-
mance status (PS = 0-1) (P < 0.0001). We also showed
that stage-modified IPI was a good predictor of overall
survival. Patients in the low risk group (stage-modified
IPI = 0-1) had an MST of 87 months (95% CI 78-95)
versus 44 months (95% CI 33-54) for those in the inter-
mediate and high risk groups (stage-modified IPI = 2-5).
In univariate analysis, advanced Lugano staging (≥ stage
II2), elevated LDH levels, poor PS, stage-modified IPI ≥
2, low albumin, bulky disease and lymphocytopenia
were all related to shorter overall survival. In multivari-
ate analysis of OS, PS (relative risk, RR = 8.02, 95% CI
3.11-20.71, P < 0.0001) and stage-modified IPI ≥ 2( R R
= 9.02, 95% CI 2.67-30.51, P < 0.0001) remained
significant predictors. Table 4 summarizes a univariate
and multivariate analysis of the factors considered as
predictors of overall survival.
Figure 2 demonstrates that the actuarial estimates of
EFS at 1 and 5 year were 77% and 52%, respectively,
with a median EFS of 57 months (95% CI 48-67). Possi-
ble predictive variables of EFS were also estimated by
univariate and multivariate analysis, as shown in Table
5. We found that PS ≥ 2 (RR: 7.45, 95% CI 2.96-18.73, P
< 0.0001), stage-modified IPI ≥ 2 (RR: 3.63, 95%CI 1.51-
8.72, P = 0.004) and low hemoglobin (RR: 2.38, 95%CI
1.08-5.27, P = 0.032) were effective predictors of EFS in
Cox multivariate analysis.
We also evaluated the impact of surgery and radio-
therapy in the management of PGL. We found that the
mean overall survival for patients treated with che-
motherapy alone was 58 months (95% CI 44-72). OS
w a s6 7m o n t h s( 9 5 %C I5 2 - 8 2 )i np a t i e n t st r e a t e dw i t h
chemotherapy combined with surgery and 73 months
(95% CI 59-87) in those treated with chemotherapy
combined with radiotherapy. However, we found no sta-
tistically significant difference between these three
groups (P > 0.05). Of the 67 B-cell lymphoma patients
who received chemotherapy, 36 patients treated with
rituximab concurrently with or followed by chemother-
apy (Table 6). Patients with rituximab therapy had a
mean survival time of 72 months (95% CI 62-81) versus
62 months (95% CI 47-76) in those without rituximab
therapy (P = 0.021).
Discussion
Primary gastric non-Hodgkin’s lymphoma comprises
about 4-20% of all non-Hodgkin lymphomas [6,11,16].
PGL is also the most common extranodal NHL in the
Hong Kong Chinese population, accounting for up to
80% of all extranodal NHL. This is higher than the
numbers reported in western countries [17]. Our analy-
sis of 57 DLBCL patients among the PGL cases showed
that the ratio of the GCB to non-GCB subtype was
1:1.85 and is similar to a previous study from Hong
Kong. In the Hong Kong study, 32 patients with DLBCL
were comprised of 10 (31.2%) GCB and 22 (68.8%) non-
GCB phenotypes [17]. However, in a study of 141
patients with primary gastric DLBCL from Japan, Italy
and France, the ratio of GCB to non-GCB phenotypes
was about 1.04:1 [18]. The ratio of GCB to non-GCB
subtypes in Chinese patients with DLBCL of PGL has
not been extensively investigated and the sample sizes
analyzed so far, including in our study, have been small
[17,18]. It will be interesting to explore differences in
the distribution of pathology subtypes between Chinese
and non-Chinese patients with PGL.
In the 69 patients who received H. pylori detection,
the incidence of H. pylori infection for cases with
Figure 1 Overall Survival of 83 Chinese Patients with PGL.
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Page 5 of 10Table 4 Risk Factors Associated with OS in 83 Chinese Patients with PGL
Univariate Analysis Multivariate Analysis
Variable Mean survival of OS
(months) (95%CI)
P value RR
(95%CI)
P value
Sex
Female 67 (55,80) 0.622
Male 52 (43,62)
Age
≤ 60 years 66 (55,76) 0.795
> 60 years 44 (34,53)
B symptoms
No 67 (55,79) 0.186
Yes 60 (49,71)
LDH
≤ 245 U/L 81 (70,91) < 0.0001 Not significant
> 245 U/L 45 (33,56)
Extranodal involvement (excluding stomach)
No 67 (58,76) 0.112
Yes 37 (15,58)
Lugano staging
I-II1 88 (78,97) < 0.0001 Not significant
≥ II2 49 (39,59)
ECOG performance status (PS)
0-1 71 (62,80) < 0.0001 8.08
(3.13, 20.89)
0.0001
≥ 2 17 (5,29)
Histological subtypes
1
DLBCL 65 (54, 76) 0.098
MALT 78 (61, 95)
T-cell lymphomas 37 (17, 59)
mIPI
0-1 87 (78,95) < 0.0001 8.49
(2.50, 28.85)
0.001
≥ 2 44 (33,54)
Bulky disease
No 73 (63,83) 0.004 Not significant
Yes 42 (28,57)
Leucocytopenia
No 65 (56,75) 0.955
Yes 39 (23,56)
Neutropenia
No 65 (55,74) 0.833
Yes 40 (24,56)
Lymphocytopenia
No 68 (59,78) 0.023 Not significant
Yes 42 (20,63)
Anemia
No 72 (58,82) 0.235
Yes 60 (47,72)
Albumin
≥ 35 g/L 73 (64,83) 0.003 Not significant
< 35 g/L 44 (29,58)
1Patients with DLBCL (57 cases), MALT lymphoma (14 cases) and T-cell lymphomas (8 cases) were included for analysis, and other histological subtypes were
excluded.
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Page 6 of 10DLBCL was lower than those with MALT lymphoma:
79% versus 92%, respectively. H. pylori is considered
linked to the development of MALT lymphoma,
although its role in DLBCL is a matter of debate
[9,10,19].
The value of possible prognostic factors such as B
symptoms, LDH levels and PS remains controversial. No
risk factors have been clearly identified in PGL so far
and the International Prognostic Index (IPI) is a com-
monly used predictive model for aggressive non-Hodg-
kin’s lymphoma. However, the role of IPI in PGL is
doubtful [1,20,21]. Since the modified-stage IPI pro-
posed by S. Cortelazzo et al. was applied in a limited
manner to patients with localized primary gastric
DLBCL (stage I-IIE) [14], the predictive value of stage-
modified IPI in advanced stage or other subtypes lym-
phoma remains unexplored. In our study, we analyzed
the clinical characteristics of Chinese patients with dif-
ferent subtypes (predominantly DLBCL) of PGL present-
ing at both limited and advanced Lugano stages. We
found that performance status and stage-modified IPI
could effectively predict prognosis of PGL.
In recent years, surgery has gradually been replaced by
radiotherapy in the treatment of PGL. However, surgery
has been seen to benefit patients who present with
hemorrhage, perforation or ileus [11,22,23]. We found
no significant difference when we compared the overall
survival of patients treated either with chemotherapy
alone or with combination therapy (chemotherapy com-
bined with radiation or with surgery). Approximately
two thirds of the patients recruited in our study pre-
sented at an advanced Lugano stage (≥ II2). We propose
that surgery or radiotherapy work by improving overall
survival in early stage PGL patients rather than
advanced cases. This might explain why we saw no sig-
nificant differences between different treatment modal-
ities in our analysis. The small sample size analyzed in
our study could be a possible reason for the lack of OS
difference between the different treatment modalities.
Rituximab, a chimeric anti-CD20 antibody, was found
to be effective in terms of improving survival rate as
well as eliciting an effective clinical response when used
in combination with conventional chemotherapy for var-
ious subtypes of B-cell lymphoma patients [24-26]. As
far as we know, there were no previous studies directly
compared immunotherapy-chemotherapy with che-
motherapy alone in PGL. The study of Wohrer et al.
showed that rituximab in addition to chemotherapy was
promising in early-stage gastric DLBCL [27]. A retro-
spective study of 75 patients in Japan also displayed an
excellent result in gastric DLBCL [28]. However, a phase
II clinical trial showed that the addition of rituximab to
standard chemotherapy did not improve the outcome in
early-stage PGL [29]. The role of rituximab in PGL
remained controversial.
In this series, our data suggested that rituximab might
improve the efficacy of chemotherapy in patients with
primary gastric B-cell lymphoma. It was speculated that
since conventional chemotherapy showed excellent
results for early-stage PGL, adding rituximab may only
have added limited incremental value [29]. The situation
was quite different in our report. Of the 36 patients who
received rituximab therapy in our study, 22 patients
(61%) had advanced disease and carried a worse prog-
nosis. The effect of rituximab could well display in
patients with advanced stage. The effect of rituximab
combined with chemotherapy in B-cell PGL remains
controversial [26,27,30]. It will be very informative to
study the exact role of rituximab in patients with PGL
in large prospective randomized clinical trials.
Conclusion
In this study, we found a much higher proportion of the
non-GCB subtype among Chinese gastric DLBCL
patients than the GCB subtype. Performance status and
stage-modified IPI were effective predictors of prognosis
in Chinese patients with primary gastric lymphoma at
all stages. Our data suggested that primary gastric B-cell
lymphoma might have better outcome with rituximab
treatment in addition to chemotherapy. More studies
are necessary, preferentially large prospective rando-
mized clinical trials to obtain more information on the
impact of the rituximab in the primary gastric B-cell
lymphoma.
Figure 2 Event-Free Survival of 83 Chinese Patients with PGL.
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Univariate Analysis Multivariate Analysis
Variable Mean survival of EFS
(month)(95%CI)
P value RR
(95%CI)
P value
Sex
Female 59 (46,73) 0.697
Male 46 (36,56)
Age
≤ 60 years 58 (47,69) 0.875
> 60 years 41 (30, 52)
B symptoms
No 59 (45,72) 0.294
Yes 53 (41,65)
LDH
≤ 245 U/L 70 (57,82) 0.001 Not significant
> 245 U/L 39 (27,51)
Extranodal involvement (excluding stomach)
No 59 (49,69) 0.160
Yes 32 (12,52)
Lugano staging
I-II1 82 (70,93) < 0.0001 Not significant
≥ II2 41 (30,51)
ECOG performance status (PS)
0-1 62 (53,72) < 0.0001 7.45
(2.96, 18.73)
0.0001
≥ 2 11 (0,24)
Histological subtypes
1
DLBCL 58 (47, 69) 0.261
MALT 73 (54, 91)
T-cell lymphomas 34 (13, 56)
mIPI
0-1 77 (65,89) < 0.0001 3.63
(1.51, 8.72)
0.004
≥ 2 37 (26,48)
Bulky disease
No 66 (55,76) 0.001 Not significant
Yes 30 (15,45)
Leucocytopenia
No 59 (49,69) 0.179
Yes 24 (5,43)
Neutropenia
No 58 (49,68) 0.372
Yes 29 (11,47)
Lymphocytopenia
No 63 (53,73) 0.001 Not significant
Yes 27 (8,46)
Anemia
No 70 (58,82) 0.007 2.38
(1.08, 5.27)
0.032
Yes 45 (33,58)
Albumin
≥ 35 g/L 67 (56,77) 0.001
< 35 g/L 33 (19,48) Not significant
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